Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus.
We report on 48 patients with carcinoma of the oesophagus treated by hyperfractionated accelerated radiotherapy. The patients, aged 46 to 93 years, were considered suitable for radiotherapy on their performance status irrespective of the presence of metastases. The radiotherapy was given three times a day over 2 weeks with a minimum of 3 h between treatments. The treatment was well tolerated acutely and to date there have been no unacceptable long-term side-effects. Dysphagia was improved in 39 (81.2%) patients. Product-limit survival was 35.7%, 18.5% and 12.3% at 1, 2 and 3 years. We conclude that this regime is feasible within the normal working day, well tolerated, effective and the shorter overall treatment duration desirable.
Sule-Suso
J
J
Department of Radiotherapy, North Staffordshire Royal Infirmary, Stoke-on-Trent, UK.
Brunt
A M
AM
Lindup
R
R
Scoble
J E
JE
D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D000368:Aged; D002277:Carcinoma / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D005591:Chemical Fractionation; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011879:Radiotherapy Dosage; D013997:Time Factors